Adicet Bio annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adicet Bio Free Cash Flow (FCF) History (ACET)
Adicet Bio reported −$97.0M in free cash flow for fiscal 2025, a decrease of $3.5M from the previous fiscal year.
View full Adicet Bio company overviewAdicet Bio free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$97.0M | −$3.5M | — | — |
| 2024 | 2024-12-31 | −$93.5M | $4.7M | — | — |
| 2023 | 2023-12-31 | −$98.2M | −$36.6M | — | — |
| 2022 | 2022-12-31 | −$61.5M | $2.6M | — | −246.29% |
| 2021 | 2021-12-31 | −$64.1M | −$21.6M | — | — |
| 2020 | 2020-12-31 | −$42.5M | −$13.6M | — | — |
| 2019 | 2019-12-31 | −$29.0M | −$9.9M | — | — |
| 2018 | 2018-12-31 | −$19.1M | −$8.0M | — | — |
| 2017 | 2017-12-31 | −$11.0M | — | — | — |
Adicet Bio quarterly free cash flow
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$20.0M | $6.7M | — | — |
| Q1 2026 | 2026-03-31 | −$21.5M | $5.4M | — | — |
| Q4 2025 | 2025-12-31 | −$20.9M | $3.4M | — | — |
| Q3 2025 | 2025-09-30 | −$22.5M | −$109,000 | — | — |
| Q2 2025 | 2025-06-30 | −$26.7M | −$3.0M | — | — |
| Q1 2025 | 2025-03-31 | −$26.9M | −$3.8M | — | — |
| Q4 2024 | 2024-12-31 | −$24.3M | −$655,000 | — | — |
| Q3 2024 | 2024-09-30 | −$22.4M | −$263,000 | — | — |
| Q2 2024 | 2024-06-30 | −$23.7M | $2.7M | — | — |
| Q1 2024 | 2024-03-31 | −$23.1M | $2.9M | — | — |
| Q4 2023 | 2023-12-31 | −$23.6M | $1.7M | — | — |
| Q3 2023 | 2023-09-30 | −$22.1M | −$2.0M | — | — |
| Q2 2023 | 2023-06-30 | −$26.4M | −$8.9M | — | — |
| Q1 2023 | 2023-03-31 | −$26.0M | −$27.5M | — | — |
| Q4 2022 | 2022-12-31 | −$25.3M | −$8.8M | — | — |
| Q3 2022 | 2022-09-30 | −$20.1M | −$3.3M | — | — |
| Q2 2022 | 2022-06-30 | −$17.6M | −$2.6M | — | — |
| Q1 2022 | 2022-03-31 | $1.5M | $17.3M | — | — |
| Q4 2021 | 2021-12-31 | −$16.5M | −$2.8M | — | — |
| Q3 2021 | 2021-09-30 | −$16.9M | −$8.8M | — | — |
| Q2 2021 | 2021-06-30 | −$14.9M | −$2.8M | — | — |
| Q1 2021 | 2021-03-31 | −$15.8M | −$7.2M | — | — |
| Q4 2020 | 2020-12-31 | −$13.7M | −$6.0M | — | — |
| Q3 2020 | 2020-09-30 | −$8.1M | −$13.1M | — | — |
| Q2 2020 | 2020-06-30 | −$12.1M | $2.1M | — | — |
| Q1 2020 | 2020-03-31 | −$8.6M | $3.4M | — | — |
| Q4 2019 | 2019-12-31 | −$7.7M | −$16.8M | — | — |
| Q3 2019 | 2019-09-30 | $5.0M | $15.8M | — | — |
| Q2 2019 | 2019-06-30 | −$14.2M | −$4.4M | — | — |
| Q1 2019 | 2019-03-31 | −$12.1M | −$4.5M | — | — |
| Q4 2018 | 2018-12-31 | $9.1M | — | — | — |
| Q3 2018 | 2018-09-30 | −$10.7M | −$6.9M | — | — |
| Q2 2018 | 2018-06-30 | −$9.8M | — | — | — |
| Q1 2018 | 2018-03-31 | −$7.6M | — | — | — |
| Q3 2017 | 2017-09-30 | −$3.9M | — | — | — |
Adicet Bio free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$42.5M to −$97.0M, a net decrease of $54.4M. Adicet Bio's latest reported quarter, Q2 2026, generated −$20.0M in free cash flow, an increase of $6.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Adicet Bio source filings ↗Community posts
Adicet reports lupus remissions and prepares pivotal study
Adicet Bio ($ACET) disclosed Phase 1 findings for its off-the-shelf CAR-T therapy prula-cel in systemic lupus erythematosus, with or without lupus nephritis. The efficacy dataset included 22 patients, with 13 followed for at least 12 months ...
